996 1030
[27]
Shore N. NX-1207: a novel investigational drug for the treatment of benign prostatic hyperplasia. Expert Opin Investig Drugs 2010;19:305–10.
[28]
Shore N, Cowan B. The potential for NX-1207 in benign prostatic hyperplasia: an update for clinicians. Ther Adv Chronic Dis 2011;2:377–83.
[29]
Shore N, Cowan BE, Wachs BH, Cline KJ, Kalota SJ, Freedman SJ. Multi-center prospective randomized double-blind study of single- injection transrectal NX-1207 in men with lower urinary tract symptoms due to benign prostatic hyperplasia Annual Meeting of the South Central Section of the American Urological Association; Boston; September 10; 2007.
[30]
Cowan B, et al. Outcome analysis 8-19 months after single treat- ment with transrectal NX-1207 inmulti-center prospective blinded randomized placebo controlled study of men with lower urinary tract symptoms due to benign prostatic hyperplasia Annual Meet- ing of the Mid-Atlantic Section of the American Urological Associ- ation; Bermuda; October 18; 2007.
[31]
Shore N, et al. A prospective randomized two dose level comparison of single-injection transrectal intraprostatic NX-1207 and finaste- ride in men with lower urinary tract symptoms due to benign prostatic hyperplasia Annual Meeting of the North Central Section of the American Urological Association; Chicago; September 25; 2008.
[32]
Buckley JT. The channel-forming toxin aerolysin. FEMS Microbiol Immunol 1992;5:13–7.
[33]
Christensson A, Laurell CB, Lilja H. Enzymatic activity of prostate- specific antigen and its reactions with extracellular serine protein- ase inhibitors. Eur J Biochem 1990;194:755–63.[34]
Froehner M, Hakenberg OW, Koch R, Schmidt U, Meye A, Wirth MP. Comparison of the clinical value of complexed PSA and total PSA in the discrimination between benign prostatic hyperplasia and pros- tate cancer. Urol Int 2006;76:27–30.
[35]
Savblom C, Malm J, Giwercman A, Nilsson JA, Berglund G, Lilja H. Blood levels of free-PSA but not complex-PSA significantly corre- lates to prostate release of PSA in semen in young men, while blood levels of complex-PSA, but not free-PSA increase with age. Prostate 2005;65:66–72.
[36]
Singh R, Browning JL, Abi-Habib R, et al. Recombinant prostate- specific antigen proaerolysin shows selective protease sensitivity and cell cytotoxicity. Anticancer Drugs 2007;18:809–16.[37]
Williams SA, Merchant RF, Garrett-Mayer E, Isaacs JT, Buckley JT, Denmeade SR. A prostate-specific antigen-activated channel-form- ing toxin as therapy for prostatic disease. J Natl Cancer Inst 2007;99:376–85.
[38]
Denmeade SR, Egerdie B, Steinhoff G, Merchant R, Abi-Habib R, Pommerville P. Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 2011;59:747–54.
[39]
Elhilali MM, Pommerville P, Yocum RC, Merchant R, Roehrborn CG, Denmeade SR. Prospective, randomized, double-blind, vehicle con- trolled, multicenter phase IIb clinical trial of the pore forming protein PRX302 for targeted treatment of symptomatic benign prostatic hyperplasia. J Urol 2013;189:1421–6.
[40]
Porpiglia F, Fiori C, Bertolo R, Garrou D, Cattaneo G, Amparore D. Temporary implantable nitinol device (TIND): a novel, minimally invasive treatment for relief of lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (BPH): feasibility, safety and functional results at 1 year of follow-up. BJU Int 2015;116:278–87.[41]
McNicholas TA. Benign prostatic hyperplasia and new treatment options – a critical appraisal of the UroLift system. Med Devices (Auckl) 2016;9:115–23.
[42]
McNicholas TA, Woo HH, Chin PT, et al. Minimally invasive pros- tatic urethral lift: surgical technique and multinational experience. Eur Urol 2013;64:292–9.
[43]
Roehrborn CG, Gange SN, Shore ND, et al. The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: the L.I.F.T. Study. J Urol 2013;190:2161–7.[44]
Roehrborn C, Gange S, Shore N, et al. Nr. 192: Long term (5 year) results from the largest, prospective, randomized, controlled study of the minimally invasive prostatic urethral lift (PUL). Eur Urol Suppl 2017;16:e334.
[45]
Sonksen J, Barber NJ, Speakman MJ, et al. Prospective, randomized, multinational study of prostatic urethral lift versus transurethral resection of the prostate: 12-month results from the BPH6 study. Eur Urol 2015;68:643–52.
[46]
Gratzke C, Barber N, Speakman MJ, et al. Prostatic urethral lift vs transurethral resection of the prostate: 2-year results of the BPH6 prospective, multicentre, randomized study. BJU Int 2017;119: 767–75.
[47]
Cantwell AL, Bogache WK, Richardson SF, et al. Multicentre pro- spective crossover study of the ‘prostatic urethral lift’ for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. BJU Int 2014;113:615–22.[48]
Chin PT, Bolton DM, Jack G, et al. Prostatic urethral lift: two-year results after treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology 2012;79:5–11.
[49]
McVary KT, Gange SN, Shore ND, et al. Treatment of LUTS second- ary to BPH while preserving sexual function: randomized controlled study of prostatic urethral lift. J Sex Med 2014;11: 279–87.[50]
Perera M, Roberts MJ, Doi SA, Bolton D. Prostatic urethral lift improves urinary symptoms and flow while preserving sexual function for men with benign prostatic hyperplasia: a systematic review and meta-analysis. Eur Urol 2015;67:704–13.
[51]
Roehrborn CG, Rukstalis DB, Barkin J, et al. Three year results of the prostatic urethral L.I.F.T. study. Can J Urol 2015;22:7772–82.[52]
Shore N, Freedman S, Gange S, et al. Prospective multi-center study elucidating patient experience after prostatic urethral lift. Can J Urol 2014;21:7094–101.[53]
Woo HH, Bolton DM, Laborde E, et al. Preservation of sexual function with the prostatic urethral lift: a novel treatment for lower urinary tract symptoms secondary to benign prostatic hy- perplasia. J Sex Med 2012;9:568–75.
[54]
Woo HH, Chin PT, McNicholas TA, et al. Safety and feasibility of the prostatic urethral lift: a novel, minimally invasive treatment for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). BJU Int 2011;108:82–8.
[55]
Rukstalis D, Rashid P, Bogache W, et al. Two year durability after crossover to the prostatic urethral lift from randomized, blinded sham. BJU Int 2016;118:14–22.[56]
Sturch P, Woo HH, McNicholas T, Muir G. Ejaculatory dysfunction after treatment for lower urinary tract symptoms: retrograde ejaculation or retrograde thinking? BJU Int 2015;115:186–7.[57]
MacRae C, Gilling P. How I do it: aquablation of the prostate using the AQUABEAM system. Can J Urol 2016;23:8590–3.
[58]
Gilling P, Reuther R, Kahokehr A, Fraundorfer M. Aquablation – image-guided robot-assisted waterjet ablation of the prostate: initial clinical experience. BJU Int 2016;117:923–9.
[59]
Gilling P, Anderson P, Tan A. Aquablation of the prostate for symptomatic benign prostatic hyperplasia: one-year results. J Urol 2017;197:1565–72.
[60]
Dixon CM, Rijo Cedano E, Mynderse LA, Larson TR. Transurethral convective water vapor as a treatment for lower urinary tract symptomatology due to benign prostatic hyperplasia using theE U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 9 8 6 – 9 9 7
996